18 November 2026 | Wednesday | News
Image Source: Public Domain
TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix
License supports lifecycle management of the PMN310 franchise, with options to extend TXP1 to ProMIS’s Parkinson’s and ALS programs
ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibodies that selectively target toxic misfolded proteins in neurodegenerative diseases, announced that it has entered into a license agreement with Ossianix, Inc. for TXP1, a next-generation brain-selective shuttling technology targeting transferrin receptor 1 (TfR1). The agreement provides ProMIS rights to use TXP1 with PMN310, its lead antibody for Alzheimer’s disease (AD), and options to apply the technology to its Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) programs.
“This partnership is in support of the long-term value of our pipeline. Our ongoing efforts with PMN310 are unaffected by this agreement and we remain committed to advancing it as an intravenous (IV) and subcutaneous product, subject to upcoming data,” said Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences. “We believe TXP1 is among the most compelling TfR1 shuttles in development. Pairing it with antibodies that are selective for toxic misfolded proteins may provide a path to a second-generation PMN310 in AD with a more convenient subcutaneous dosing schedule and lower cost of goods and to next-generation candidates in our pipeline.”
TXP1 is built on a deimmunized, single-domain VNAR antibody scaffold that is significantly smaller than a conventional antibody. In preclinical studies reported by Ossianix, including studies in non-human primates, TXP1 increased delivery of a therapeutic antibody to the brain by more than 65-fold, with no accumulation observed in the liver, spleen, lung, kidney, bone marrow, heart or muscle. Ossianix has also reported a favorable PK profile with prolonged brain exposure, binding that does not compete with transferrin, and minimal impact on reticulocyte levels, an effect that has been reported with some TfR1-targeting approaches. Based on these preclinical data, ProMIS believes TXP1 has a differentiated profile among TfR1-based shuttles.
“We are proud to partner with ProMIS and see this agreement as strong validation of TXP1’s profile as a next-generation TfR1-targeting delivery technology,” said Frank Walsh, CEO of Ossianix. “By pairing our deimmunized VNAR platform—which binds a unique epitope—with ProMIS’s selective antibodies, we see a compelling opportunity to enable more convenient dosing across Alzheimer’s and expand into additional neurodegenerative programs.”
Under the terms of the agreement, Ossianix will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments, as well as royalties on global net sales. ProMIS also holds options to apply TXP1 to PMN442, its antibody targeting alpha-synuclein (implicated in Parkinson’s disease and dementia with Lewy bodies), and PMN267, its antibody targeting TDP-43 (implicated in ALS and frontotemporal dementia). ProMIS intends to fund its short-term obligations under the agreement from existing cash resources and does not expect the agreement to change its previously disclosed cash runway through 2027.
© 2026 Biopharma Boardroom. All Rights Reserved.